Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has reported success in preclinical research with their drug Rutherrin®, which has shown promise in repurposing non-cancer drugs for cancer therapy. By enhancing the efficacy of drugs like Withaferin A, Amiodarone, and Metformin, which are traditionally used for other ailments, Rutherrin® could significantly reduce time and costs associated with cancer treatment development. This innovative approach leverages established drug safety profiles to tackle multiple cancer indications more effectively.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
